106 related articles for article (PubMed ID: 19179076)
21. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking.
Ren JX; Li LL; Zheng RL; Xie HZ; Cao ZX; Feng S; Pan YL; Chen X; Wei YQ; Yang SY
J Chem Inf Model; 2011 Jun; 51(6):1364-75. PubMed ID: 21618971
[TBL] [Abstract][Full Text] [Related]
22. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
23. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
Qian K; Wang L; Cywin CL; Farmer BT; Hickey E; Homon C; Jakes S; Kashem MA; Lee G; Leonard S; Li J; Magboo R; Mao W; Pack E; Peng C; Prokopowicz A; Welzel M; Wolak J; Morwick T
J Med Chem; 2009 Apr; 52(7):1814-27. PubMed ID: 19256503
[TBL] [Abstract][Full Text] [Related]
24. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
25. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
26. Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design.
Good AC; Liu J; Hirth B; Asmussen G; Xiang Y; Biemann HP; Bishop KA; Fremgen T; Fitzgerald M; Gladysheva T; Jain A; Jancsics K; Metz M; Papoulis A; Skerlj R; Stepp JD; Wei RR
J Med Chem; 2012 Mar; 55(6):2641-8. PubMed ID: 22339127
[TBL] [Abstract][Full Text] [Related]
27. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
28. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors.
Barreca ML; De Luca L; Iraci N; Rao A; Ferro S; Maga G; Chimirri A
J Chem Inf Model; 2007; 47(2):557-62. PubMed ID: 17274611
[TBL] [Abstract][Full Text] [Related]
29. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
30. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors.
Gavara L; Suchaud V; Nauton L; Théry V; Anizon F; Moreau P
Bioorg Med Chem Lett; 2013 Apr; 23(8):2298-301. PubMed ID: 23499503
[TBL] [Abstract][Full Text] [Related]
31. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
32. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
33. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
34. Protein flexibility in ligand docking and virtual screening to protein kinases.
Cavasotto CN; Abagyan RA
J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
[TBL] [Abstract][Full Text] [Related]
35. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.
Tong Y; Stewart KD; Thomas S; Przytulinska M; Johnson EF; Klinghofer V; Leverson J; McCall O; Soni NB; Luo Y; Lin NH; Sowin TJ; Giranda VL; Penning TD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5206-8. PubMed ID: 18790640
[TBL] [Abstract][Full Text] [Related]
36. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.
Zippo A; De Robertis A; Serafini R; Oliviero S
Nat Cell Biol; 2007 Aug; 9(8):932-44. PubMed ID: 17643117
[TBL] [Abstract][Full Text] [Related]
37. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.
Xiang Y; Hirth B; Asmussen G; Biemann HP; Bishop KA; Good A; Fitzgerald M; Gladysheva T; Jain A; Jancsics K; Liu J; Metz M; Papoulis A; Skerlj R; Stepp JD; Wei RR
Bioorg Med Chem Lett; 2011 May; 21(10):3050-6. PubMed ID: 21507633
[TBL] [Abstract][Full Text] [Related]
38. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
39. In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase.
Brooks WH; McCloskey DE; Daniel KG; Ealick SE; Secrist JA; Waud WR; Pegg AE; Guida WC
J Chem Inf Model; 2007; 47(5):1897-905. PubMed ID: 17676832
[TBL] [Abstract][Full Text] [Related]
40. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
